Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Urogen Pharma Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
URGN
Nasdaq
8731
https://www.urogen.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Urogen Pharma Ltd
UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
- Mar 17th, 2024 12:55 pm
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript
- Mar 15th, 2024 2:30 pm
UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges
- Mar 14th, 2024 1:32 pm
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
- Mar 14th, 2024 1:10 pm
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
- Mar 14th, 2024 12:00 pm
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 8th, 2024 1:00 pm
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
- Mar 4th, 2024 1:00 pm
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
- Feb 26th, 2024 1:00 pm
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
- Feb 23rd, 2024 11:20 am
UroGen Pharma to Participate at Upcoming Investor Conferences
- Feb 1st, 2024 1:00 pm
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
- Jan 24th, 2024 1:00 pm
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
- Jan 17th, 2024 1:00 pm
UroGen Pharma to Participate in the B. Riley Healthcare Conference
- Jan 11th, 2024 1:00 pm
Shareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years ago
- Nov 27th, 2023 12:42 pm
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript
- Nov 15th, 2023 6:50 pm
UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials
- Nov 14th, 2023 5:19 pm
UroGen Pharma Reports Third Quarter 2023 Financial Results
- Nov 14th, 2023 1:00 pm
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
- Nov 13th, 2023 1:00 pm
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
- Nov 7th, 2023 1:00 pm
Institutional investors own a significant stake of 50% in UroGen Pharma Ltd. (NASDAQ:URGN)
- Oct 30th, 2023 11:12 am
Scroll